182 related articles for article (PubMed ID: 11804704)
21. The screening of Alzheimer's patients with CSF biomarkers, modulates the distribution of APOE genotype: impact on clinical trials.
Dumurgier J; Laplanche JL; Mouton-Liger F; Lapalus P; Indart S; Prévot M; Peoc'h K; Hugon J; Paquet C
J Neurol; 2014 Jun; 261(6):1187-95. PubMed ID: 24728335
[TBL] [Abstract][Full Text] [Related]
22. Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease.
Mehta PD; Pirttilä T; Mehta SP; Sersen EA; Aisen PS; Wisniewski HM
Arch Neurol; 2000 Jan; 57(1):100-5. PubMed ID: 10634455
[TBL] [Abstract][Full Text] [Related]
23. Association between butyrylcholinesterase and cerebrospinal fluid biomarkers in Alzheimer's disease patients.
Gabriel AJ; Almeida MR; Ribeiro MH; Durães J; Tábuas-Pereira M; Pinheiro AC; Pascoal R; Santana I; Baldeiras I
Neurosci Lett; 2017 Feb; 641():101-106. PubMed ID: 28108398
[TBL] [Abstract][Full Text] [Related]
24. APOE ε4 moderates abnormal CSF-abeta-42 levels, while neurocognitive impairment is associated with abnormal CSF tau levels in HIV+ individuals - a cross-sectional observational study.
Cysique LA; Hewitt T; Croitoru-Lamoury J; Taddei K; Martins RN; Chew CS; Davies NN; Price P; Brew BJ
BMC Neurol; 2015 Apr; 15():51. PubMed ID: 25880550
[TBL] [Abstract][Full Text] [Related]
25. Cystatin C levels are positively correlated with both Abeta42 and tau levels in cerebrospinal fluid in persons with Alzheimer's disease, mild cognitive impairment, and healthy controls.
Sundelöf J; Sundström J; Hansson O; Eriksdotter-Jönhagen M; Giedraitis V; Larsson A; Degerman-Gunnarsson M; Ingelsson M; Minthon L; Blennow K; Kilander L; Basun H; Lannfelt L
J Alzheimers Dis; 2010; 21(2):471-8. PubMed ID: 20555147
[TBL] [Abstract][Full Text] [Related]
26. The Role of Apolipoprotein E ε4 in Early and Late Mild Cognitive Impairment.
Luo Y; Tan L; Therriault J; Zhang H; Gao Y;
Eur Neurol; 2021; 84(6):472-480. PubMed ID: 34340229
[TBL] [Abstract][Full Text] [Related]
27. Stability of CSF beta-amyloid(1-42) and tau levels by APOE genotype in Alzheimer patients.
Huey ED; Mirza N; Putnam KT; Soares H; Csako G; Levy JA; Copenhaver B; Cohen RM; Sunderland T
Dement Geriatr Cogn Disord; 2006; 22(1):48-53. PubMed ID: 16682793
[TBL] [Abstract][Full Text] [Related]
28. Differences in the Abeta40/Abeta42 ratio associated with cerebrospinal fluid lipoproteins as a function of apolipoprotein E genotype.
Fagan AM; Younkin LH; Morris JC; Fryer JD; Cole TG; Younkin SG; Holtzman DM
Ann Neurol; 2000 Aug; 48(2):201-10. PubMed ID: 10939571
[TBL] [Abstract][Full Text] [Related]
29. The effect of APOE genotype on the delivery of DHA to cerebrospinal fluid in Alzheimer's disease.
Yassine HN; Rawat V; Mack WJ; Quinn JF; Yurko-Mauro K; Bailey-Hall E; Aisen PS; Chui HC; Schneider LS
Alzheimers Res Ther; 2016 Jun; 8():25. PubMed ID: 27358067
[TBL] [Abstract][Full Text] [Related]
30. Quantification of total apolipoprotein E and its isoforms in cerebrospinal fluid from patients with neurodegenerative diseases.
Minta K; Brinkmalm G; Janelidze S; Sjödin S; Portelius E; Stomrud E; Zetterberg H; Blennow K; Hansson O; Andreasson U
Alzheimers Res Ther; 2020 Feb; 12(1):19. PubMed ID: 32054532
[TBL] [Abstract][Full Text] [Related]
31. CSF beta-amyloid 1-42 and tau in Tunisian patients with Alzheimer's disease: the effect of APOE epsilon4 allele.
Smach MA; Charfeddine B; Lammouchi T; Harrabi I; Ben Othman L; Dridi H; Bennamou S; Limem K
Neurosci Lett; 2008 Aug; 440(2):145-9. PubMed ID: 18555606
[TBL] [Abstract][Full Text] [Related]
32. Cerebrospinal Fluid Particles in Alzheimer Disease and Parkinson Disease.
Yang Y; Keene CD; Peskind ER; Galasko DR; Hu SC; Cudaback E; Wilson AM; Li G; Yu CE; Montine KS; Zhang J; Baird GS; Hyman BT; Montine TJ
J Neuropathol Exp Neurol; 2015 Jul; 74(7):672-87. PubMed ID: 26083568
[TBL] [Abstract][Full Text] [Related]
33. Genetic variants in PSEN2 and correlation to CSF β-amyloid42 levels in AD.
Lebedeva E; Stingl JC; Thal DR; Ghebremedhin E; Strauss J; Özer E; Bertram L; von Einem B; Tumani H; Otto M; Riepe MW; Högel J; Ludolph AC; von Arnim CA
Neurobiol Aging; 2012 Jan; 33(1):201.e9-18. PubMed ID: 20850903
[TBL] [Abstract][Full Text] [Related]
34. Increased PCSK9 Cerebrospinal Fluid Concentrations in Alzheimer's Disease.
Zimetti F; Caffarra P; Ronda N; Favari E; Adorni MP; Zanotti I; Bernini F; Barocco F; Spallazzi M; Galimberti D; Ricci C; Ruscica M; Corsini A; Ferri N
J Alzheimers Dis; 2017; 55(1):315-320. PubMed ID: 27662294
[TBL] [Abstract][Full Text] [Related]
35. Associations between cerebral small-vessel disease and Alzheimer disease pathology as measured by cerebrospinal fluid biomarkers.
Kester MI; Goos JD; Teunissen CE; Benedictus MR; Bouwman FH; Wattjes MP; Barkhof F; Scheltens P; van der Flier WM
JAMA Neurol; 2014 Jul; 71(7):855-62. PubMed ID: 24818585
[TBL] [Abstract][Full Text] [Related]
36. Increased CSF cortisol in AD is a function of APOE genotype.
Peskind ER; Wilkinson CW; Petrie EC; Schellenberg GD; Raskind MA
Neurology; 2001 Apr; 56(8):1094-8. PubMed ID: 11320185
[TBL] [Abstract][Full Text] [Related]
37. Memory Correlates of Alzheimer's Disease Cerebrospinal Fluid Markers: A Longitudinal Cohort Study.
Reijs BLR; Ramakers IHGB; Köhler S; Teunissen CE; Koel-Simmelink M; Nathan PJ; Tsolaki M; Wahlund LO; Waldemar G; Hausner L; Vandenberghe R; Johannsen P; Blackwell A; Vanderstichele H; Verhey F; Visser PJ
J Alzheimers Dis; 2017; 60(3):1119-1128. PubMed ID: 28984585
[TBL] [Abstract][Full Text] [Related]
38. Baseline CSF/Serum-Ratio of Apolipoprotein E and Rate of Differential Decline in Alzheimer's Disease.
Schmidt C; Gerlach N; Schmitz M; Thom T; Kramer K; Friede T; Zerr I
J Alzheimers Dis; 2015; 48(1):189-96. PubMed ID: 26401939
[TBL] [Abstract][Full Text] [Related]
39. Accelerated decline in apolipoprotein E-epsilon4 homozygotes with Alzheimer's disease.
Craft S; Teri L; Edland SD; Kukull WA; Schellenberg G; McCormick WC; Bowen JD; Larson EB
Neurology; 1998 Jul; 51(1):149-53. PubMed ID: 9674794
[TBL] [Abstract][Full Text] [Related]
40. Effects of Alzheimer's disease-associated risk loci on cerebrospinal fluid biomarkers and disease progression: a polygenic risk score approach.
Martiskainen H; Helisalmi S; Viswanathan J; Kurki M; Hall A; Herukka SK; Sarajärvi T; Natunen T; Kurkinen KM; Huovinen J; Mäkinen P; Laitinen M; Koivisto AM; Mattila KM; Lehtimäki T; Remes AM; Leinonen V; Haapasalo A; Soininen H; Hiltunen M
J Alzheimers Dis; 2015; 43(2):565-73. PubMed ID: 25096612
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
